Chronic Myeloproliferative Neoplasms: Clinical and Molecular Genetics

Maher Albitar, Health Discovery Corporation, Savannah, Georgia, USA

Published online: October 2011

DOI: 10.1002/9780470015902.a0006104.pub2

Chronic myeloproliferative neoplasms (previously called myeloproliferative diseases) are group of haematopoietic neoplasms characterised by clonal proliferation of differentiated cells from the myeloid lineage. This includes granulocytes, erythrocytes and megakaryocytes. In general, the course of these neoplasms is chronic and some patients may live more than 20 years and die from other causes, however, in some patients, they may manifest aggressively and kill patients in short time. Significant progress have been made in understanding the molecular basis of these diseases and recently new pharmaceutical agents have been developed that specifically target these molecular abnormalities and converted these neoplasms to chronic diseases to live with as any other chronic disease. We find in this group of diseases chronic myeloid leukaemia and polycythaemia vera, which are perhaps the most molecularly defined two neoplasms. The BCR-ABL1 fused gene is the cause of the first neoplasm and the mutated JAK2 gene cause the second disease, both of which are targeted in the current treatment of these two diseases.

Key Concepts

  • Mutations cause the uncontrolled growth of cells, but these cells are capable of differentiation.
  • The ability of these leukaemic cells to differentiate leads to their death at some point making these diseases less aggressive than acute leukaemias.
  • Chromosomal translocations and mutations in specific genes are implicated in these groups of diseases.
  • Most of the genomic abnormalities in these diseases lead to activating specific kinases and this leads to uncontrolled cell proliferation.
  • By targeting these kinases, cell growth can be controlled and these diseases can be managed successfully.
  • Translocations may lead to fusing two genes and the expression of a fused protein or may lead to a change in the regulation of the gene and its deregulation.
  • Activation of a gene via translocation is usually into other genomic locus and a specific partner gene, but occasionally can be promiscuous and accept other partners.
  • Historically the Philadelphia chromosome is considered the first hint for the fact cancer is genomic disease was discovered in CML, which is one of the cMPNs discussed here.

Keywords: chronic myeloid leukaemia; eosinophilia; mastocytosis; myeloproliferative neoplasms; Philadelphia chromosome; BCR-ABL; polycythaemia vera; myelofibrosis; essential thrombocythaemia

Figure 1. Schematic map of the BCR, ABL1 and BCR–ABL1 fusion genes. Exons of the ABL1 gene are shown as solid boxes and exons of the BCR gene are shown as shaded boxes. Vertical arrows indicate breakpoint regions.
close
 References
    Antonioli E, Guglielmelli P, Pancrazzi A et al. (2005) Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 19(10): 1847–1849.
    Baxter EJ, Scott LM, Campbell PJ et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464): 1054–1061.
    Brcic L, Vuletic LB, Stepan J et al. (2007) Mast-cell sarcoma of the tibia. Journal of Clinical Pathology 60(4): 424–425.
    Campbell PJ, Griesshammer M, Dohner K et al. (2006) V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 107(5): 2098–2100.
    Charrette EE, Mariano AV and Laforet EG (1966) Solitary mast cell ‘tumor’ of lung. Its place in the spectrum of mast cell disease. Archives of Internal Medicine 118(4): 358–362.
    Chott A, Guenther P, Huebner A et al. (2003) Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma. American Journal of Surgical Pathology 27(7): 1013–1019.
    Guenther PP, Huebner A, Sobottka SB et al. (2001) Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy. Journal of Pediatric Hematology and Oncology 23(2): 134–138.
    Hasegawa T, Suzuki K, Sakamoto C et al. (2003) Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia. Blood 101(3): 1164–1171.
    Horny HP, Parwaresch MR, Kaiserling E et al. (1986) Mast cell sarcoma of the larynx. Journal of Clinical Pathology 39(6): 596–602.
    Horny HP, Sotlar K and Valent P (2007) Mastocytosis: state of the art. Pathobiology 74(2): 121–132.
    Kako S, Kanda Y, Sato T et al. (2007) Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation. American Journal of Hematology 82(5): 386–390.
    Kojima M, Nakamura S, Itoh H et al. (1999) Mast cell sarcoma with tissue eosinophilia arising in the ascending colon. Modern Pathology 12(7): 739–743.
    Kralovics R, Passamonti F, Buser AS et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine 352(17): 1779–1790.
    Kudo H, Morinaga S, Shimosato Y et al. (1988) Solitary mast cell tumor of the lung. Cancer 61(10): 2089–2094.
    Ma W, Kantarjian H, Zhang X et al. (2009) Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. Journal of Molecular Diagnostics 11(1): 49–53.
    Ma W, Zhang X, Wang X et al. (2011) MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders. Diagnostic Molecular Pathology 20(1): 34–39.
    Mc Lornan DP, Percy MJ, Jones AV, Cross NC and Mc Mullin MF (2005) Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation. Haematologica 90(12): 1696–1697.
    Mesa RA (2007) Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders. Hematology American Society of Hematology Education Program 355–362.
    ePath O'Brian S, Berman E, Devetten MP et al. (2008) Chronic Myelogenous Leukemia. National Comprehensive Cancer Network (NCCN) Practice Guidelines in Oncology November 26(1). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
    Onida F, Kantarjian HM, Smith TL et al. (2002) Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 99(3): 840–849.
    Patnaik MM, Rindos M, Kouides PA, Tefferi A and Pardanani A (2007) Systemic mastocytosis: a concise clinical and laboratory review. Archives of Pathology & Laboratory Medicine 131(5): 784–791.
    book Swerdlow SH, Campo E, Harris NL et al. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4 edn. Lyon: IARC.
    Tefferi A, Thiele J, Orazi A et al. (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110(4): 1092–1097.
    Tefferi A and Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22(1): 14–22.
    Teofili L, Giona F, Martini M et al. (2007) Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. Journal of Clinical Oncology 25(9): 1048–1053.
 Further Reading
    Klco JM, Vij R, Kreisel FH, Hassan A and Frater JL (2010) Molecular pathology of myeloproliferative neoplasms. American Journal of Clinical Pathology 133(4): 602–615.
    Radich JP (2010) Chronic myeloid leukemia 2010: where are we now and where can we go? Hematology American Society of Hematology Education Program 2010: 122–128.
    Thiele J (2009) Philadelphia chromosome-negative chronic myeloproliferative disease. American Journal of Clinical Pathology 132(2): 261–280.
    Vladareanu AM, Müller-Tidow C, Bumbea H and Radesi S (2010) Molecular markers guide diagnosis and treatment in Philadelphia chromosome-negative myeloproliferative disorders. Oncology Reports 23(3): 595–604.
    Wadleigh M and Tefferi A (2010) Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. International Journal of Hematology 91(2): 174–179.

Related Sub-Topics:

Specific Genetic Disorders | Mutational Mechanisms of Genetic Disease | Cancer Genetics
Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

Article Title: Chronic Myeloproliferative Neoplasms: Clinical and Molecular Genetics
 
How to Cite close
Albitar, Maher(Oct 2011) Chronic Myeloproliferative Neoplasms: Clinical and Molecular Genetics. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0006104.pub2]